Summit Therapeutics Inc. — Director's Dealing 2024

Jan 4, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-01-02

Reporting Person: Xia Yu (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-02	Stock Option (right to buy)	$2.64	A	35000	Acquired	2034-01-02	Common Stock (35000)	Direct
2024-01-02	Stock Option (right to buy)	$2.64	A	200000	Acquired	2034-01-02	Common Stock (200000)	Direct

Footnotes

F1: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date.

F2: Not applicable.

F3: The option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on January 2, 2025.